Designing molecular diagnostics for current tuberculosis drug regimens

References

• World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva, Switzerland; 2020. https://www.who.int/publications/i/item/WHO-UCN-TB-2022-2
   Google Scholar
• World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva, Switzerland; May 2022.
   Google Scholar
• Kaniga K, Hasan R, Jou R, et al. Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): a 5-year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates. J Clin Microbiol. 2022;60(1):e0291920.
   PubMed Web of Science ®Google Scholar
• Ghodousi A, Rizvi AH, Khanzada FM, et al. In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE _Ala63Pro mutation during treatment in a pre-XDR TB patient. Eur Respir J. 2021;59(3):2102102.
   Web of Science ®Google Scholar
• Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2021;22(4):496–506.
   PubMed Web of Science ®Google Scholar
• Huang T-S, Liu Y-C, Sy C-L, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother. 2008;52:2226–2227.
   PubMed Web of Science ®Google Scholar
• Wasserman S, Louw G, Ramangoaela L, et al. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. J Antimicrob Chemother. 2019;74:2377–2384.
   PubMed Web of Science ®Google Scholar
• Bloemberg GV, Keller PM, Stucki D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. New Engl J Med. 2015;373:1986–1988.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva, Switzerland. 2021. https://www.who.int/publications/i/item/9789240028173
   Google Scholar
• The CRyPTIC Consortium. Epidemiological cutoffs for a 96-well broth microtitre plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis. medRxiv. 2021; doi:10.1101/2021.02.24.21252386.
   Google Scholar
• Ismail NA, Ismail F, Joseph L, et al. Epidemiological cut-offs for sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing. Sci Rep. 2020;10:1013.
   PubMedGoogle Scholar
• Hatami H, Sotgiu G, Bostanghadiri N, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384.
   PubMed Web of Science ®Google Scholar
• Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrug-resistant TB (the NExT study): A multicenter, randomized controlled trial. Am J Resp Crit Care Med. 2022;205(10):1214–1227.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Target product profile survey: next-generation drug-susceptibility testing at peripheral centres. Geneva, Switzerland; 2021. https://www.who.int/publications/i/item/9789240032361
   Google Scholar
• Borisov SE, D’Ambrosio L, Centis R, et al. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. J Infect. 2019;78:35–39.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56:3271–3276.
   PubMed Web of Science ®Google Scholar
• Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in Southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe. 2020;1:e165–e174.
   PubMedGoogle Scholar
• Villellas C, Coeck N, Meehan CJ, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2016;72:684–690.
   Web of Science ®Google Scholar
• Xu J, Wang B, Hu M, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61:e00239–17.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New Engl J Med. 2014;371:723–732.
   PubMed Web of Science ®Google Scholar
• Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47:564–574.
   PubMed Web of Science ®Google Scholar
• Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. New Eng J Med. 2022;387:810–823.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. 2018.
   Google Scholar
• Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One. 2014;9:e102135.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen J, Cui P, et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2015;70:2507–2510.
   PubMed Web of Science ®Google Scholar
• Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60:4590–4599.
   PubMed Web of Science ®Google Scholar
• Torrea G, Coeck N, Desmaretz C, et al. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. J Antimicrob Chemother. 2015;70:2300–2305.
   PubMed Web of Science ®Google Scholar
• Zimenkov DV, Nosova EY, Kulagina EV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother. 2017;72:1901–1906.
   PubMed Web of Science ®Google Scholar
• Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58:2979–2981.
   PubMed Web of Science ®Google Scholar
• Rodwell TC. personal communication. Information about the WHO catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, version 2.0. 18 January 2023.
   Google Scholar
• Kadura S, King N, Nakhoul M, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother. 2020;75:2031–2043.
   PubMed Web of Science ®Google Scholar
• Ismail N, Rivière E, Limberis J, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe. 2021;2:e604–e616.
   PubMedGoogle Scholar
• Huitric E, Verhasselt P, Koul A, et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2010;54:1022–1028.
   PubMed Web of Science ®Google Scholar
• Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. New Eng J Med. 2020;382:893–902.
   PubMed Web of Science ®Google Scholar
• Klopper M, Heupink TH, Hill-Cawthorne G, et al. A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic. BMC Med. 2020;18:24.
   PubMed Web of Science ®Google Scholar
• Xpert MTB-XDR ENGLISH Package Insert 302-3514 Rev A.
   Google Scholar
• Cabibbe AM, Spitaleri A, Battaglia S, et al. Application of targeted next-generation sequencing assay on a portable sequencing platform for culture-free detection of drug-resistant tuberculosis from clinical samples. J Clin Microbiol. 2021;58:e00632–20.
   Web of Science ®Google Scholar
• World Health Organization. Public call for whole genome sequencing and phenotypic data from clinical isolates of M. tuberculosis complex. Geneva, Switzerland. 14 February 2022.
   Google Scholar
• Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings. Trans R Soc Trop Med Hyg. 2016;110:163–172.
   PubMed Web of Science ®Google Scholar
• Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Exp Rev Anti Infect Ther. 2016;14:901–915.
   PubMed Web of Science ®Google Scholar
• Du J, Gao J, Yu Y, et al. Low rate of acquired linezolid resistance in multidrug-resistant tuberculosis treated with bedaquiline-linezolid combination. Front Microbiol. 2021;12:1014.
   Web of Science ®Google Scholar
• Hillemann D, Rüsch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother. 2008;52:800–801.
   PubMed Web of Science ®Google Scholar
• Beckert P, Hillemann D, Kohl TA, et al. Rplc T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 2012;56:2743–2745.
   PubMed Web of Science ®Google Scholar
• Richter E, Rüsch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007;51:1534–1536.
   PubMed Web of Science ®Google Scholar
• Perdigão J, Maltez F, Machado D, et al. Beyond extensively drug-resistant tuberculosis in Lisbon, Portugal: a case of linezolid resistance acquisition presenting as an iliopsoas abscess. Int J Antimicrob Agents. 2016;48:569–570.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA briefing document pretomanid tablet, 200 mg Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC).
   Google Scholar
• Nasiri MJ, Zangiabadian M, Arabpour E, et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Int J Infect Dis. 2022;S1201-9712(22)00125-4.
   Web of Science ®Google Scholar
• McGrath M, Gey van Pittius NC, van Helden PD, et al. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69:292–302.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position statement on the use of delamanid for multidrug-resistant tuberculosis. Geneva, Switzerland. 2018.
   Google Scholar
• Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother. 2008;62:1037–1045.
   PubMed Web of Science ®Google Scholar
• Gurumurthy M, Mukherjee T, Dowd CS, et al. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J. 2012;279:113–125.
   PubMed Web of Science ®Google Scholar
• Stinson K, Kurepina N, Venter A, et al. MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother. 2016;60:3316–3322.
   PubMed Web of Science ®Google Scholar
• Köser CU, Javid B, Liddell K, et al. Drug-resistance mechanisms and tuberculosis drugs. Lancet. 2015;385:305–307.
   PubMed Web of Science ®Google Scholar
• Haver HL, Chua A, Ghode P, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:5316–5323.
   PubMed Web of Science ®Google Scholar
• Bashiri G, Antoney J, Jirgis ENM, et al. A revised biosynthetic pathway for the cofactor F420 in prokaryotes. Nature Comm. 2019;10:1558.
   PubMed Web of Science ®Google Scholar
• Rifat D, Li S-Y, Ioerger T, et al. Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;65:e01948–20.
   PubMed Web of Science ®Google Scholar
• Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. New Engl J Med. 2012;366:2151–2160.
   PubMed Web of Science ®Google Scholar
• Schena E, Nedialkova L, Borroni E, et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTECTM MGITTM 960 system. J Antimicrob Chemother. 2016;71:1532–1539.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003;7:6–21.
   PubMed Web of Science ®Google Scholar
• Lamont EA, Dillon NA, Baughn AD. The bewildering antitubercular action of pyrazinamide. Microbiol Mol Biol Rev. 2020;84:e00070–19.
   PubMed Web of Science ®Google Scholar
• Zignol M, Cabibbe AM, Dean AS, et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis. 2018;18:675–683.
   PubMed Web of Science ®Google Scholar
• du Cros P, Khamraev A, Tigay Z, et al. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan. ERJ Open Res. 2021;7:537–2020.
   PubMedGoogle Scholar
• Yee DP, Menzies D, Brassard P. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. Int J Tuberc Lung Dis. 2012;16:604–609.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Geneva, Switzerland; 2021. https://www.who.int/publications/i/item/9789240029415
   Google Scholar
• Zhang Y, Chiu Chang K, Leung C-C, et al. ‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg Microb Infect. 2012;1:1–4.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Aoki S, Saito T, et al.: total-deletion mutation of pncA as a new mechanism of pyrazinamide resistance in Mycobacterium tuberculosis - The first report from Japan. Open Forum Infect Dis. 1696;2014(1):S453–S453.
   Google Scholar
• Whitfield MG, Engelthaler DM, Allender C, et al. Comparative performance of genomic methods for the detection of pyrazinamide resistance and heteroresistance in Mycobacterium tuberculosis. J Clin Microbiol. 2021;60:e0190721.
   PubMed Web of Science ®Google Scholar
• Cui Z, Wang J, Lu J, et al. Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide. J Clin Microbiol. 2013;51:1374–1380.
   PubMedGoogle Scholar
• Rueda D, Bernard C, Gandy L, et al. Estimation of pyrazinamidase activity using a cell-free in vitro synthesis of pncA and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis. Int J Mycobacteriol. 2018;7:16–25.
   PubMed Web of Science ®Google Scholar
• Köser CU, Feuerriegel S, Summers DK, et al. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother. 2012;56:6080–6087.
   PubMed Web of Science ®Google Scholar
• Colman R. Seq&Treat Phase I: an analytical evaluation of three targeted next-generation sequencing solutions for the detection of drug-resistant TB. Presented virtually at: union World Conference on Lung Health 2021. Oral Abstract Session. 2021 Oct 22.
   Google Scholar
• Treatment Action Group (TAG). Pipeline report 2020: tuberculosis diagnostics. 2020. Available from: https://www.finddx.org/wp-content/uploads/2020/11/TAG-pipeline_TB_Diagnostics_2020_final.pdf.
   Google Scholar
• World Health Organization. Guidance for the surveillance of drug resistance in tuberculosis. 6th ed. Geneva, Switzerland; 2021. https://www.who.int/publications/i/item/9789240018020
   Google Scholar
• Cepheid. Xpert MTB/RIF Package Insert. 2019.
   Google Scholar
• MolBio. TruenatTM MTB-RIF Dx [Internet]. 2020 [cited 2020 Jun 16]. Available from: http://www.molbiodiagnostics.com/product_details.php?id = 25.
   Google Scholar
• Jouet A, Gaudin C, Badalato N, et al. Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. Eur Respir J. 2021;57:2002338.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global TB programme meeting report: High-priority target product profiles for new tuberculosis diagnostics: Report of a consensus meeting. WHO Meeting Report Geneva, Switzerland; 2014.
   Google Scholar
• World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex. Appendix 3: Target Product Profile - Detection of resistance associated mutations in Mycobacterium tuberculosis complex utilizing Next Generation Sequencing; 2018.
   Google Scholar
• Verma R, Patil S, Zhang N, et al. A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment. Am J Respir Crit Care Med. 2021;204:1317–1326.
   PubMed Web of Science ®Google Scholar
• Rancoita PM V, Cugnata F, Gibertoni Cruz AL, et al. Validating a 14-drug microtiter plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62:e00344–18.
   PubMed Web of Science ®Google Scholar
• Study Record Detail: Bioneer Accupower Q-RFIA PCR Kit Clinical Evaluation. [cited 2022 Feb 14] Available from:https://clinicaltrials.gov/ct2/show/NCT05117788 https://clinicaltrials.gov/ct2/show/NCT05117788.
   Google Scholar
• Pang Y, Dong H, Tan Y, et al. Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China. Sci Rep. 2016;6:25330.
   PubMed Web of Science ®Google Scholar
• Igarashi Y, Chikamatsu K, Aono A, et al. Laboratory evaluation of the Anyplex™ II MTB/MDR and MTB/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance. Diag Microbiol Infect Dis. 2017;89:276–281.
   PubMed Web of Science ®Google Scholar
• Spannaus R, personal communication. Information about the FluoroType XDR assay (Hain Lifescience). 2 February 2022.
   Google Scholar
• Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in Southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe. 2020;1:e165–e174.
   PubMedGoogle Scholar
• Günther G, Van Leth F, Alexandru S, et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis. 2015;21:409–416.
   PubMed Web of Science ®Google Scholar